Vertical: Healthcare59 Sections
Market Size (2019)
$461.60B
Projected (2035)
$1.38T
CAGR (2019–2035)
7.1%
Key Players
10+
This report covers Device Type Market with forecasts from 2019 to 2035. 10 key companies are profiled.
The Device Type Market market is projected to grow at a CAGR of 7.1% from 2019 to 2035.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The medical devices market is a rapidly growing sector within healthcare which is driven by technological innovation, demographic changes and increasing healthcare expenditure. Increasing prevalence of chronic diseases, an aging global population and increasing demand for minimally invasive procedures are fueling the adoption of advanced medical devices. Technological advancements such as robotics, AI-assisted diagnostics, wearable devices and smart implants are continuously expanding the portfolios of the product where regulatory frameworks like FDA approvals and ISO standards ensure safety, quality and reliability. The market also benefits from expanding healthcare infrastructure which emerges in the economies and creates new growth opportunities. However, the challenges such as high R&D costs, stringent regulatory requirements and intense competition persist. Overall, the medical devices market thrives on innovation and patient-centric solutions, presenting significant opportunities for manufacturers and healthcare providers alike.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
—
Historical Period
2019 – 2035
Forecast Period
2019 – 2035
Primary Interviews
150+
Historical performance and future projections
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Market estimates by geography (2035)
InsightGlobal leads with $1.38T by 2035, while Asia-Pacific is projected to grow fastest at a 9.2% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2019 | 2019 | 2035 | CAGR | SHARE |
|---|---|---|---|---|---|
| Global | $461.60B | $785.75B | $1.38T | 7.1% | 45% |
| North America | $197.13B | $344.19B | $618.59B | 7.4% | 20% |
| Europe | $151.50B | $225.57B | $339.47B | 5.2% | 11% |
| Asia-Pacific | $82.37B | $165.95B | $336.71B | 9.2% | 11% |
| APAC | $82.37B | $165.95B | $336.71B | 9.2% | 11% |
| Rest of the World | $30.60B | $50.04B | $82.77B | 6.4% | 3% |
| Total | $1.04T | $1.79T | $3.09T | 7.1% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Device Type Market covering market dynamics, competitive landscape, and strategic outlook.
The Device Type Market market is projected to reach $1.38T by 2035, growing at 7.1% CAGR.
Introduction
The medical devices market is a rapidly growing sector within healthcare which is driven by technological innovation, demographic changes and increasing healthcare expenditure. Increasing prevalence of chronic diseases, an aging global population and increasing demand for minimally invasive procedures are fueling the adoption of advanced medical devices. Technological advancements such as robotics, AI-assisted diagnostics, wearable devices and smart implants are continuously expanding the portfolios of the product where regulatory frameworks like FDA approvals and ISO standards ensure safety, quality and reliability. The market also benefits from expanding healthcare infrastructure which emerges in the economies and creates new growth opportunities. However, the challenges such as high R&D costs, stringent regulatory requirements and intense competition persist. Overall, the medical devices market thrives on innovation and patient-centric solutions, presenting significant opportunities for manufacturers and healthcare providers alike.
GROWING GERIATRIC POPULATION AND CHRONIC DISEASE BURDEN
The global increase in the geriatric population is a significant driver of the medical devices market. As people get aged, they are more susceptible to chronic and age-related health conditions such as cardiovascular diseases, diabetes, cancer, arthritis and stroke. These conditions require continuous monitoring with timely diagnosis and effective management where all of which create increasing demand for advanced medical devices which include diagnostic tools, monitoring systems, surgical instruments and rehabilitation equipment.
In addition to aging, the increasing prevalence of chronic diseases among all age groups is accelerating the need for medical interventions. Improvements in healthcare access, better disease awareness and early diagnosis have increased the detection of chronic conditions which in turn drives the adoption of medical devices. Devices that support long-term care, personalized treatment and preventive healthcare are becoming increasingly essential in modern healthcare systems. Overall, the combination of an expanding elderly population and the growing burden of chronic diseases is fueling the global demand for medical devices. This trend encourages the innovation in device development and adoption which offers the sustained opportunities for manufacturers to provide solutions that improve the outcomes of patient and increase the efficiency of healthcare.
TECHNOLOGICAL ADVANCEMENTS AND INTEGRATION OF AI IN DEVICES
Rapid technological advancements are transforming the medical devices market by increasing the precision, efficiency and effectiveness of healthcare delivery. Innovations in imaging, robotics, wearable sensors, and minimally invasive surgical tools are enabling more accurate diagnostics and improved patient outcomes. These developments reduce procedural risks, shorten recovery times, and streamline workflows which make the healthcare systems more efficient and reliable. As a result, healthcare providers are increasingly adopting advanced devices which drive the growth of the overall market.
The integration of artificial intelligence (AI) and machine learning into medical devices further accelerates their utility and adoption. AI-powered diagnostic tools can analyse complex datasets in real time enables the early disease detection and predictive analytics. Smart monitoring systems can track patient vitals continuously alerts the providers of healthcare to anomalies before they escalate into critical conditions. Such capabilities not only improve clinical decision-making but also reduce healthcare costs and enhance patient safety.
Overall, the convergence of technological innovations and AI integration is a significant growth driver for the medical devices market. Manufacturers are investing in research and development to introduce intelligent, connected and automated devices that meets the evolving clinical needs. This trend is creating opportunities for next-generation medical devices that support precision medicine, personalized care and data-driven healthcare solutions thereby expanding the market globally.
RISING ADOPTION OF OPHTHALMIC VISCOELASTIC DEVICES IN CATARACT AND REFRACTIVE SURGERIES
Ophthalmic viscoelastic devices (OVDs) play an important role in modern eye surgeries, particularly cataract and refractive procedures. These viscoelastic solutions help maintain intraocular space to protect delicate ocular tissues and facilitate precise manipulation during surgery. As cataract and refractive surgeries continue to rise globally due to aging populations and increasing vision-related health awareness, the demand for OVDs has grown significantly which makes them an essential component of ophthalmic surgical procedures.
The growing adoption of advanced surgical techniques, such as phacoemulsification and femtosecond laser-assisted surgeries has further boosted the utilization of viscoelastic devices. Surgeons prefer high-quality OVDs for their consistency, biocompatibility and ability to improve the patient outcomes by decreasing the complications. This has led hospitals and eye care centers to invest more in premium viscoelastic products which drives the growth of the revenue for manufacturers in this specialized segment.
Overall, the increasing prevalence of cataract and refractive surgeries are combined with the critical role of viscoelastic solutions in improving surgical precision and safety is a strong growth driver for the ophthalmic medical devices market. Continuous product innovation, including next-generation biocompatible formulations which is expected to further accelerate adoption and expand opportunities in this niche but rapidly growing segment.
The government programs and policies are actively incorporating RPM into standard care pathways, thereby creating institutional demand for the devices and technologies that power remote monitoring. For example, the U.S. Centers for Medicare & Medicaid Services (CMS) now requires home health agencies to report telehealth use on claims, using specific HCPCS codes for services delivered via two-way audio/video in home health settings. Also, CMS reimburses remote patient monitoring services covering both device provision, data transmission, and clinical monitoring/management time making RPM a viable revenue stream for providers. Because Medicare broadly covers RPM for chronic and acute conditions, government spending will increasingly support these services s policies evolve for e ample, proposals like the “ pandin emote onitorin ccess ct” seek to rela illin requirements and broaden access), the market for connected physiological monitoring devices, wearables, sensors, and associated infrastructure stands to grow substantially. -GENERATION BIOCOMPATIBLE VISCOELASTIC SOLUTIONS Next-generation biocompatible viscoelastic solutions principally improved sodium hyaluronate (hyaluronic acid, HA) formulations and novel polysaccharide or hydrogel systems are being actively developed to improve safety, tissue protection and handling during ophthalmic procedures and intraocular device implantation.
U.S. government sources document both the clinical role of ophthalmic Visco surgical devices (OVDs) in protecting intraocular structures during cataract and other anterior-segment surgeries and the regulatory pathway these materials follow These sources show that refinements in molecular weight, crosslinking and rheologic profile translate into measurable surgical benefits for the better endothelial protection, chamber maintenance, and reduced complications, which also triggers the specific regulatory reviews (510(k)/PMA submissions) and recognized standards for OVD testing.
STRINGENT REGULATORY REQUIREMENTS AND LENGTHY APPROVAL PROCESSES
Regulatory regimes for medical devices such as the U.S. Food and Drug Administration (FDA) under Title 21 of the Code of Federal Regulations (CFR) and the European Union’s Medical Device Regulation (MDR, Regulation (EU) 2017/745) impose rigorous controls on device design, manufacturing, testing, labeling, clinical evaluation, post-market surveillance, and change control. For example, in the U.S., devices classified as Class III must undergo a full Premarket Approval (PMA) process, where manufacturers must submit valid scientific evidence to demonstrate safety and effectiveness before marketing. In the EU, under MDR, manufacturers must follow strict conformity assessment procedures (often involving notified bodies), maintain detailed technical documentation, and comply with enhanced vigilance and transparency obligations through EUDAMED. These layered requirements increase both the complexity and cost of bringing a new device to market, creating a high barrier for entrants or for incremental innovations.
The timeline for regulatory review is frequently long and unpredictable, which delays market entry and increases financial risk. In the U.S., the 510(k)-clearance pathway itself can take several months, while PMA reviews often take one to two years or more. n the EU, delays are further exacerbated by limited capacity of notified bodies and evolving guidance under MDR, making conformity assessment and certification often stretch beyond initial expectations. Because companies must often invest heavily in clinical trials, quality systems, post-market studies, and documentation well before any revenue is realized, these long lead times serve as a strong deterrent to investment in medical device innovation, particularly for smaller firms or novel technologies.
HIGH COST AND LIMITED REIMBURSEMENT FOR PREMIUM VISCOELASTIC SOLUTIONS
Premium viscoelastic solutions used during ophthalmic surgeries like cataract extraction, glaucoma procedures, corneal transplantation and vitreoretinal surgery often come with higher material costs relative to standard viscoelastics. Because premium products (for example, those with better purity, longer retention, specific rheological properties, combination formulations, or enhanced biocompatibility) cost more to develop, manufacture, and supply, hospitals and surgical centers need to charge more. But many public health systems, insurance schemes, and government procurement policies impose limits on the amounts that will be reimbursed for such medical supplies or surgical consumables. When the reimbursement rates are fixed (e.g. under a predefined package or scheme) and do not fully reflect the premium cost, providers have to absorb the excess cost or pass it on to patients, which reduces demand, discourages uptake, and limits the market growth of premium viscoelastic solutions.
Moreover, limited reimbursement can stem from lack of specific coverage codes or regulatory recognition for premium viscoelastics as being distinct from standard viscoelastic. In many reimbursement systems, consumables are bundled into procedure‐based payments, or only the cost of a “standard” device is accepted. If a premium viscoelastic is used, the extra cost above the standard may not be reimbursed, or only partially so, leading to out-of-pocket expense for patients. This acts as a barrier both for providers in choosing to use premium formulations, and for manufacturers trying to bring them into markets dominated by lower cost alternatives. This particularly affects smaller or lower-income healthcare systems or regions, where cost sensitivity is high and reimbursement flexibility is limited.
The government programs and policies are actively incorporating RPM into standard care pathways, thereby creating institutional demand for the devices and technologies that power remote monitoring. For example, the U.S. Centers for Medicare & Medicaid Services (CMS) now requires home health agencies to report telehealth use on claims, using specific HCPCS codes for services delivered via two-way audio/video in home health settings. Also, CMS reimburses remote patient monitoring services covering both device provision, data transmission, and clinical monitoring/management time making RPM a viable revenue stream for providers. Because Medicare broadly covers RPM for chronic and acute conditions, government spending will increasingly support these services. As policies evolve (for example, proposals like the “Expanding Remote Monitoring Access Act” seek to relax billing requirements and broaden access), the market for connected physiological monitoring devices, wearables, sensors, and associated infrastructure stands to grow substantially.
R&D ADVANCEMENTS IN NEXT-GENERATION BIOCOMPATIBLE VISCOELASTIC SOLUTIONS
Next-generation biocompatible viscoelastic solutions principally improved sodium hyaluronate (hyaluronic acid, HA) formulations and novel polysaccharide or hydrogel systems are being actively developed to improve safety, tissue protection and handling during ophthalmic procedures and intraocular device implantation. U.S. government sources document both the clinical role of ophthalmic Visco surgical devices (OVDs) in protecting intraocular structures during cataract and other anterior-segment surgeries and the regulatory pathway these materials follow These sources show that refinements in molecular weight, crosslinking and rheologic profile translate into measurable surgical benefits for the better endothelial protection, chamber maintenance, and reduced complications, which also triggers the specific regulatory reviews (510(k)/PMA submissions) and recognized standards for OVD testing.
MARKET FACTOR ANALYSIS
Supply Chain
The supply chain of Medical Devices Market consists of the stages of component analysis, manufacturers, distribution, and end users.
MEDICAL DEVICES MARKET: Supply chain
R&D DESIGNING
In the medical devices market, the supply chain begins with R&D designing, where scientific innovation and regulatory alignment intersect. This stage involves identifying clinical needs, designing prototypes, testing materials for biocompatibility, and ensuring compliance with standards set by agencies like the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH). Publicly funded research, often supported by the National Science Foundation (NSF) and NIH Small Business Innovation Research (SBIR) programs, contributes significantly to early-stage development. The focus here is on integrating engineering design with safety, usability, and data from preclinical and clinical testing. R&D design efficiency directly influences downstream costs, time-to-market, and overall product competitiveness within the medical device supply chain.
MANUFACTURERS
Manufacturing in the medical devices supply chain encompasses scaling prototypes into compliant, high-quality production systems under Good Manufacturing Practice (GMP) and Quality System Regulation (QSR) requirements outlined by the FDA (21 CFR Part 820). This stage includes sourcing raw materials, component fabrication, sterilization, and assembly under strict traceability and quality control processes. Many U.S. and international manufacturers collaborate with certified suppliers to maintain compliance and meet regulatory audits. Continuous process validation, automation, and digital quality management systems help improve production efficiency and product reliability. The manufacturing phase thus serves as the operational backbone of the medical device supply chain, balancing innovation with safety and regulatory accountability.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 109 companies operating in the Device Type Market market, including revenue, employee count, and market positioning where available.
Showing 109 of 109 companies
Siemens is Europe's largest industrial technology group and, on the evidence of its own fiscal 2025 accounts, one of the very few diversified industrials that has successfully converted a hardware conglomerate into a software-and-automation compounder without sacrificing scale. Revenue of €78.9 billion and net income of €10.4 billion in FY2025 sit alongside a €117 billion order backlog and a 42,400-strong patent estate. The company's structural advantage is the pairing of installed-base automation hardware — SIMATIC, SINAMICS, SENTRON, Trainguard — with a first-tier industrial software franchise built through Mentor Graphics, Altair and Dotmatics, monetized through the Siemens Xcelerator platform. The planned spin-off of Siemens Healthineers, scheduled for a shareholder vote in February 2027, will strip roughly €23 billion of revenue but leave a more focused, higher-multiple portfolio of Digital Industries, Smart Infrastructure and Mobility. The strategic bet is explicit: industrial AI, electrification of data centres, and doubling digital revenue by 2030. --- ### What Siemens does — the company's own characterization Siemens describes itself in its FY2025 corporate boilerplate as a technology company focused on industry, infrastructure, mobility and healthcare, whose stated purpose is to create technology to transform the everyday. The formulation Siemens uses consistently across FY2025–FY2026 filings is that it combines the real and the digital worlds to help customers accelerate digital and sustainability transformations — making factories more efficient, cities more liveable, and transport more sustainable. Since FY2024 the company has appended a claim to leadership in industrial AI, positioning its domain knowledge as the differentiator that makes generative and predictive AI usable in physical industrial settings. ### Independent characterization Siemens is best understood not as a conglomerate but as three tightly coupled franchises plus a soon-to-be-detached fourth: **(a) An automation installed-base business with a software annuity attached (Digital Industries).** The economic engine here is the sale of controllers, drives, CNCs and industrial networking hardware into discrete and process manufacturing, followed by decades of engineering-software attach. Siemens' EDA business (formerly Mentor Graphics) and its PLM/simulation stack (NX, Teamcenter, Simcenter, now Altair) are genuinely tier-one franchises competing head-on with Dassault Systèmes, PTC, Cadence and Synopsys — not adjuncts to hardware. Digital Industries software revenue reached €1,790 million in Q3 FY2026 alone, up 16% year-over-year. **(b) A late-cycle electrification and buildings business riding a structural capex wave (Smart Infrastructure).** This is currently Siemens' best-performing franchise, with Q3 FY2026 orders of €8,002 million, up 40% nominally and 42% comparably, driven explicitly by large data-centre contracts in the US and Europe. Q3 FY2026 profit margin reached 20.0%. This is the segment most directly levered to the AI-infrastructure buildout. **(c) A long-cycle project and systems business with multi-decade service tails (Mobility).** Rolling stock, rail infrastructure, signalling and maintenance contracts. Order intake is lumpy — Q3 FY2026 included a €2.2 billion Swiss double-deck train order, a €2.0 billion UK extended-maintenance contract, and a €0.6 billion German battery-train service contract — but converts into decades of high-visibility service revenue. **(d) A consolidated but exiting medtech business (Siemens Healthineers).** 69% owned at Sept 30, 2025; reduced to approximately 67% subsequently. Siemens intends to distribute 30 percentage points of that stake directly to shareholders and, over the medium term, reduce the residual holding to a financial asset. **(e) A captive finance arm (Siemens Financial Services).** Total assets of €33,365 million at June 30, 2026. SFS both supports industrial sales through equipment and project finance and runs a proprietary debt and equity book. Its Q3 FY2026 EBT of €238 million included a €156 million gain from selling a UK equity stake — a reminder that SFS earnings are structurally lumpier than industrial earnings. ### Revenue model and mix Siemens does not disclose a full product / service / subscription / licence split at group level. What is disclosed: The strategically important trend is Digital Industries' transition to a software-as-a-service model, which the Supervisory Board explicitly cited when extending Cedrik Neike's contract. SaaS conversion depresses reported revenue in transition years — a partial explanation for DI's FY2025 revenue decline of 4% against 8% order growth. ### Value chain position, customers and end markets Siemens sits at the specification and control layer of industrial value chains rather than at the commodity component layer. Its products are typically designed into customer plants, buildings, grids and rolling stock at the engineering stage, creating switching costs measured in years. **Customer types:** discrete manufacturers (automotive, electronics, machine building, aerospace); process industries (chemicals, pharmaceuticals, food and beverage, oil and gas, water); semiconductor and electronics designers (EDA); hyperscale and colocation data-centre operators; commercial and institutional building owners; electric utilities and distribution network operators; national and municipal rail operators and rolling-stock leasing companies; hospitals and diagnostic laboratories (via Healthineers); and life-sciences R&D organizations (via Dotmatics). **End markets served:** factory and process automation; industrial and engineering software; electrical distribution and low/medium-voltage electrification; data-centre power infrastructure; building automation, fire safety and security; e-mobility charging; grid software and automation; passenger and freight rail; medical imaging, diagnostics and radiation oncology; and equipment/project finance. **Geographic exposure (FY2025 revenue):** Europe/C.I.S./Africa/Middle East €36,933m (46.8%); Americas €25,758m (32.6%); Asia and Australia €16,224m (20.6%). Germany alone was €11,646m and the United States €22,097m — meaning the US is now Siemens' single largest country market by a factor of nearly two over its home market.
Company Headquarters: Michigan, US Founded: 1941 Workforce: ~51,000 Company Working: Stryker is engaged in developing, manufacturing, and marketing specialty surgical and medical products. Its products include implants, biologics, surgical, neurologic, ear, throat, interventional pain equipment, endoscopic, surgical navigation, communications, and digital imaging systems. The company also offers products for patient handling and emergency medical equipment. It operates through three major segments: medical & surgical equipment (MedSurg), orthopedics, and neurotechnology & spine. Stryker has been focused on providing automation solutions in its product portfolio. It has a presence in over 75 countries across the globe.
Company Headquarters: Massachusetts, US Founded: 1979 Workforce: ~36,000 Company Working: Boston Scientific Corporation is a worldwide developer, manufacturer, and marketer of medical devices used in a range of interventional medical specialties. The company collaborates with healthcare professionals to develop a broad portfolio of meaningful innovations that improve outcomes, reduce costs, and increase efficiencies. Its product portfolio is majorly divided into endoscopy, interventional cardiology, neuromodulation, peripheral interventions, rhythm management, and urology & pelvic health. In addition, Boston Scientific serves hospitals, clinics, outpatient facilities and medical offices across the world. Boston Scientific Corporation's manufacturing facilities are located across Malaysia, the US, and Ireland. Apart from this, it has a presence in countries like Japan, the Netherlands, France, Poland, India, China, Turkey, South Africa, and Singapore.
15 interactive charts drawn from the Device Type Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Device Type By End User
Device Type By Application
Device Type By Orthopaedic Viscoelastic Solutions
Device Type By Ophthalmic Viscoelastic Solutions (Ovds)
Device Type By Viscoelastic Solutions
Device Type By Monitoring Devices
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
